Daniel Winokur, MD
Hematology & Oncology · Worcester, MANPI 1609230580
Payments from drug & device makers
Across 21 payments — averaging $15,849 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$292K
- Takeda Pharmaceuticals U.S.A., Inc.$41K
- Apellis Pharmaceuticals, Inc.$74
What the payments were for
- Consulting fees$7,22599%
- Food & beverage$741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 11 | $291,545 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $41,220 |
| Apellis Pharmaceuticals, Inc. | 2 | $74 |
How this compares
$332,839 in reported general payments places this provider in the 70th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 23 | $398,106 |
| CalquenceAcalabrutinib Maleate | 21 | $316,088 |
| BrukinsaZanubrutinib | 17 | $259,431 |
| ImbruvicaIbrutinib | 13 | $196,187 |
| RetevmoSelpercatinib | 12 | $136,274 |
| SprycelDasatinib | 11 | $105,658 |
| EliquisApixaban | 79 | $55,446 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $12,940 |
| OxycontinOxycodone Hcl | 11 | $9,379 |
| Sodium Chloride0.9 % Sodium Chloride | 26 | $2,738 |
| Acyclovir | 70 | $1,424 |
| Dexamethasone | 53 | $817 |
| Hydroxyurea | 41 | $691 |
| Ondansetron Hcl | 52 | $689 |
| Lidocaine | 12 | $661 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Worcester
- Austin KimWorcester$19.3M
- Kriti MittalWorcester$1.7M
- William WalshWorcester$1.6M
- Jan CernyWorcester$1.5M
- Viola ZhuWorcester$1.5M
- Matthew DavidsBoston$58.6M
- Nadine TungBoston$32.4M
- Jorge CastilloBoston$31.2M
- Daniel DeangeloBoston$28.5M
- Sara TolaneyBoston$20.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.